Punjab’s health authorities have ordered an immediate halt to the release, distribution, and supply of a batch of Glycosting injection after reports of a suspected adverse drug reaction.
The Directorate of Drug Control, Punjab, issued the medicine stoppage alert under Alert No. 125/2026.
The affected product is Glycosting 1ml injection, which contains glycopyrrolate 0.5mg and neostigmine methylsulfate 2.5mg. The alert identifies the affected batch as BBG11, with an expiry date of January 2028.
Authorities said the product was reported to have caused suspected adverse drug reactions, including severe bradycardia, or an abnormally slow heart rate, at multiple healthcare facilities across Punjab.
The Provincial Quality Control Board has directed that the medicine be stopped as a precaution while further investigation and regulatory action are carried out.
Manufacturers and market authorization holders have been told to immediately stop the release, distribution and supply of the affected batch and submit relevant manufacturing, quality-control, distribution, complaint and pharmacovigilance records.
Pharmacies, wholesalers, distributors and healthcare facilities have also been instructed to stop administering, dispensing, selling, supplying or otherwise distributing the batch and quarantine any remaining stock.
Healthcare facilities have been advised to report inventory and consumption records to the relevant drug inspector.
Patients and consumers have also been advised not to use or receive the affected batch as a precaution.
The post Punjab Suspends Glycosting Injection Supply appeared first on ProPakistani.
